Skip to main content
Trending this week: Beyond RTRt Models: The Hidden Challenges of Implementation https://bit.ly/3ycJ82P
34.236.191.0

Guidance for Industry PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance

Category

Document

Published on CMKC

Abstract

This guidance is intended to describe a regulatory framework (Process Analytical Technology, PAT) that will encourage the voluntary development and implementation of innovative pharmaceutical development, manufacturing, and quality assurance. Working with existing regulations, the Agency has developed an innovative approach for helping the pharmaceutical industry address anticipated technical and regulatory issues and questions. This guidance is written for a broad industry audience in different organizational units and scientific disciplines. To a large extent, the guidance discusses principles with the goal of highlighting opportunities and developing regulatory processes that encourage innovation. In this regard, it is not a typical Agency guidance. FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

Journal

FDA. 2004, 1-16

Type of publication

Document

Affiliations

  • U.S. Department of Health and Human Services
  • Center for Drug Evaluation and Research (CDER)

Article Classification

Other

Classification Areas

  • PAT
  • Regulatory

Tags